Nivolumab plus ipilimumab has also been approved for BRAF V600 wild-type and BRAF V600 mutation-positive unresectable or metastatic melanoma (CheckMate 067), urothelial carcinoma (UC) (CheckMate 901), HCC (CheckMate 040) and also non-small cell lung cancer (NSCLC) with PD-L1 tumor expression ≥ 1% (CheckMate 227). Here, BRAF is linked to hepatocellular carcinoma.